{"id":2632,"date":"2015-11-04T20:15:00","date_gmt":"2015-11-04T20:15:00","guid":{"rendered":"https:\/\/cdafound.org\/?p=2632"},"modified":"2025-01-15T20:35:40","modified_gmt":"2025-01-15T20:35:40","slug":"the-estimated-future-disease-burden-of-hepatitis-c-virus-in-the-netherlands-with-different-treatment-paradigms","status":"publish","type":"post","link":"https:\/\/cdafound.org\/fr\/the-estimated-future-disease-burden-of-hepatitis-c-virus-in-the-netherlands-with-different-treatment-paradigms\/","title":{"rendered":"La charge de morbidit\u00e9 future estim\u00e9e du virus de l&#039;h\u00e9patite C aux Pays-Bas avec diff\u00e9rents paradigmes de traitement"},"content":{"rendered":"<h2 class=\"wp-block-heading\">R\u00e9sum\u00e9<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">Contexte et objectifs<\/h3>\n\n\n\n<p>La pr\u00e9valence de l&#039;infection par le virus de l&#039;h\u00e9patite C (VHC) aux Pays-Bas est faible (pr\u00e9valence anti-VHC 0,22%). Le traitement tout oral avec des antiviraux \u00e0 action directe (AAD) est tol\u00e9rable et efficace mais co\u00fbteux. Notre analyse a projet\u00e9 la future charge de morbidit\u00e9 li\u00e9e au VHC aux Pays-Bas en appliquant diff\u00e9rents sc\u00e9narios de traitement. <\/p>\n\n\n\n<h3 class=\"wp-block-heading\">M\u00e9thodes<\/h3>\n\n\n\n<p>En utilisant une approche de mod\u00e9lisation, la taille de la population vir\u00e9mique du VHC aux Pays-Bas en 2014 a \u00e9t\u00e9 estim\u00e9e \u00e0 l&#039;aide des donn\u00e9es disponibles et du consensus d&#039;experts. Le sc\u00e9nario de base (bas\u00e9 sur la situation n\u00e9erlandaise actuelle) et diff\u00e9rents sc\u00e9narios de traitement (avec une efficacit\u00e9 accrue, une utilisation du traitement et des diagnostics accrus) ont \u00e9t\u00e9 mod\u00e9lis\u00e9s et la charge de morbidit\u00e9 future du VHC a \u00e9t\u00e9 pr\u00e9vue pour chaque sc\u00e9nario. <\/p>\n\n\n\n<h3 class=\"wp-block-heading\">R\u00e9sultats<\/h3>\n\n\n\n<p>Le nombre estim\u00e9 de personnes atteintes d&#039;une infection vir\u00e9mique par le VHC aux Pays-Bas en 2014 \u00e9tait de 19 200 (pr\u00e9valence 0,12%). D&#039;ici 2030, ce nombre devrait diminuer de 45% dans le sc\u00e9nario de base et de 85% si le nombre de patients trait\u00e9s augmente. En outre, on estime que le nombre de personnes atteintes de carcinome h\u00e9patocellulaire et de d\u00e9c\u00e8s li\u00e9s au foie diminue de 19% et 27%, respectivement, dans le sc\u00e9nario de base, mais peuvent tous deux \u00eatre encore diminu\u00e9s de 68% lorsqu&#039;on se concentre sur le traitement des patients VHC au stade de = F2.<\/p>\n\n\n\n<p><strong>Des pays:<\/strong> Les Pays-Bas<\/p>\n\n<div class=\"wp-block-buttons is-content-justification-center is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button is-style-outline is-style-outline--1\"><a class=\"wp-block-button__link has-text-color wp-element-button\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26582807\" target=\"_blank\" rel=\"noreferrer noopener\">Lire le rapport complet<\/a><\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Summary Background &amp; Aims Prevalence of hepatitis C virus (HCV) infection in the Netherlands is low (anti-HCV prevalence 0.22%). All-oral treatment with direct-acting antivirals (DAAs) is tolerable and effective but expensive. Our analysis projected the future HCV-related disease burden in the Netherlands by applying different treatment scenarios. Methods Using a modelling approach, the size of [&hellip;]<\/p>\n","protected":false},"author":24,"featured_media":3496,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[9],"tags":[10],"publication-author":[1249,1243,1244,1088,494,497,1250,1245,1248,1251,1247,1242,1246],"class_list":["post-2632","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-publication","tag-hcv","publication-author-croes-ea","publication-author-de-knegt-rj","publication-author-de-vree-jm","publication-author-prins-m","publication-author-razavi-h","publication-author-razavi-shearer-d","publication-author-reesink-hw","publication-author-van-der-meer-aj","publication-author-van-santen-dk","publication-author-veldhuijzen-ik","publication-author-willemse-sb","publication-author-zaaijer-hl","publication-author-zuure-fr"],"acf":[],"_links":{"self":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts\/2632","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/users\/24"}],"replies":[{"embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/comments?post=2632"}],"version-history":[{"count":6,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts\/2632\/revisions"}],"predecessor-version":[{"id":7592,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts\/2632\/revisions\/7592"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/media\/3496"}],"wp:attachment":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/media?parent=2632"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/categories?post=2632"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/tags?post=2632"},{"taxonomy":"publication-author","embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/publication-author?post=2632"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}